Paper Details

  1. Home
  2. Paper Details

Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.

Author: BoivinGuy, PiretJocelyne

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Antiviral agents targeting the viral DNA polymerase are currently used to treat human cytomegalovirus (HCMV) infections, but they can cause serious side effects. This article examines two new HCMV inhibitors: letermovir (LMV) and maribavir (MBV). LMV targets the viral terminase complex and has been approved for the prophylaxis of HCMV infection in hematopoietic stem cell transplant (HSCT) recipients. MBV inhibits the viral pUL97 kinase and is effective for the treatment of HCMV infections, including those resistant to other drugs. These novel inhibitors offer promising alternatives for the prevention and treatment of HCMV infections.
Paper Details　
Original Abstract of the Article :
The prevention and treatment of human cytomegalovirus (HCMV) infections is based on the use of antiviral agents that currently target the viral DNA polymerase and that may cause serious side effects. The search for novel inhibitors against HCMV infection led to the discovery of new molecular targets...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.antiviral.2019.01.011

データ提供：米国国立医学図書館（NLM）

New Hope for Fighting the CMV Virus

The fight against human cytomegalovirus (CMV) infections has been a long and arduous journey, much like a camel trekking across the vast desert. Traditional antiviral treatments target the viral DNA polymerase, but often come with unpleasant side effects. This study presents exciting new research into novel inhibitors targeting the viral terminase complex and the viral pUL97 kinase. These novel inhibitors, letermovir (LMV) and maribavir (MBV), offer promising new avenues for treating CMV infections.

A New Weapon in the Antiviral Arsenal

The study highlights the potential of LMV and MBV to revolutionize the treatment of CMV infections. LMV, by targeting the terminase complex, prevents the packaging of viral DNA into capsids, effectively stopping the virus in its tracks. MBV, on the other hand, inhibits the pUL97 kinase activity, disrupting the virus’s ability to mature and spread. These findings suggest that these compounds may be effective in treating CMV infections, including those that are resistant to current therapies.

Hope for a Brighter Future in CMV Treatment

The development of LMV and MBV has brought renewed hope for patients suffering from CMV infections. These novel drugs offer the potential for safer and more effective treatment options. As researchers continue to explore the mechanisms of these inhibitors and their long-term effects, we can look forward to a future where CMV infections are no longer a daunting threat.

Dr.Camel's Conclusion

The discovery of LMV and MBV is a significant step forward in the battle against CMV infections. These new drugs represent a beacon of hope for patients who have struggled with this debilitating virus. The future of CMV treatment looks brighter than ever, offering the promise of safer and more effective therapies for those in need.

Date :
  1. Date Completed 2020-03-13
  2. Date Revised 2020-03-13
Further Info :

Pubmed ID

30690043

DOI: Digital Object Identifier

10.1016/j.antiviral.2019.01.011

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.